In Brief: Cholestech/Metra Biosystems
This article was originally published in The Gray Sheet
Executive SummaryCholestech/Metra Biosystems: Sign agreement to develop and market a cassette for the Cholestech L-D-X point-of-care diagnostic system to assess bone resorption. The new cassette will utilize Metra's Pyrilinks-D urine assay, which was cleared by FDA in December 1995 ("The Gray Sheet" Jan. 25, 1996, In Brief). Under the agreement, Cholestech will market the test through its existing distribution channels in the U.S., while the firms will work together to market and distribute the tests internationally. The agreement also provides for the development of cassettes for additional Metra assays that would be added on to the Cholestech system. Metra made "a small equity investment" in Cholestech and will make additional investments "based upon the achievement of certain product development milestones," Cholestech says...
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.